• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Pexeva (paroxetine mesylate) tablets

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)

 

December 2012

Summary View

 

(Serotonin Toxicity associated with co-administration with Linezolid and Methylene Blue)

 

WARNINGS AND PRECAUTIONS

Somnolence/Sedation and Dizziness
  • During the 12-week, controlled study in patients with PHN, somnolence was reported in 10% of patients treated with 1,200 mg of Horizant per day compared with 8% of patients receiving placebo…
Discontinuation of Horizant
  • In patients with PHN receiving Horizant twice daily, the dose should be reduced to once daily for 1 week prior to discontinuation to minimize the potential of withdrawal seizure

 

January 2010 

Summary View

 

WARNINGS

Usage in Pregnancy
  • Teratogenic Effects: Epidemiological studies have shown that infants exposed to paroxetine in the first trimester of pregnancy have an increased risk of congenital malformations, particularly cardiovascular malformations. The findings from these studies are summarized...